Ipilimumab vs Tofacitinib

## Ipilimumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Tofacitinib**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

**Tofacitinib**: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Tofacitinib — 3.2 hours.

## Chemical Properties

**Molecular Formula**: Ipilimumab — N/A; Tofacitinib — C16H20N6O.

**Molecular Weight**: Ipilimumab — N/A; Tofacitinib — 312.3700 g/mol.

**Type**: Ipilimumab — Antibody; Tofacitinib — Small molecule.